Edition:
United Kingdom

People: ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

9.54USD
22 Aug 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$9.54
Open
--
Day's High
--
Day's Low
--
Volume
2
Avg. Vol
741,529
52-wk High
$12.21
52-wk Low
$2.23

Nussbaum, Ran 

Mr. Ran Nussbaum is Independent Director of the Company. Mr. Nussbaum has been a director since November 2017. Mr. Nussbaum is a managing partner and co-founder of The Pontifax Group (founded in 2004). The fund runs more than 50 portfolio companies all around the globe. Prior to joining Pontifax, he was a partner at Israel’s largest business intelligence and strategic consulting firm. He currently serves as a board member on many of Pontifax’s portfolio companies, including, VBI Vaccines, UroGen Pharma, Eloxx Pharmaceuticals, Keros Therapeutics (as chairman) and served as a board member of Kite Pharma, Inc. until its acquisition by Gilead Sciences, Inc. in October 2017.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 71,188
Fiscal Year Total, USD 71,188

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Patrick Zenner

110,485

Peter Lawrence

1,168,540

Paolo Pucci

1,744,530

Marc Schegerin

--

Brian Schwartz

1,057,610

Timothy Barabe

92,438
As Of  31 Dec 2018